

In the Claims

1.-64. (Cancelled)

65. (Currently Amended) A process for treating fibroses comprising administering a therapeutically effective amount of a pharmaceutical composition comprising at least one biocompatible polymer ~~selected from the group consisting of RGTA-1112 (CM₂DPheS₂) and RGTA-1113 (CM₃DTyrS₂)~~ having the general formula (I):



wherein:

A is a glucose monomer;

X is COOH or COONa;

Y is SO₃H or SO₃⁻;

Z is a tyrosine or phenylalanine residue optionally substituted with Y, wherein Z is linked to the glucose monomer via -CH₂C(=O)- ;

a represents the number of monomers A such that the mass of said polymers of formula (I) is greater than approximately 5,000 Da;

x represents the percentage of glucose monomers A that bear a X group, and x is statistically about 28.9% when Z is Phe, and statistically about 19.8% when Z is Tyr,

y represents the percentage of glucose monomers A that bear a Y group, and y is statistically about 56.2% when Z is Phe, and statistically about 65.9% when Z is Tyr, and

z represents the percentage of glucose monomers A by the groups Z, and z is statistically about 17.9% when Z is Phe, and about 28.9% when Z is Tyr.

66.-68. (Cancelled)

69. (New) The process of Claim 65 where

x is 28.9% when Z is Phe and is 19.8% when Z is Tyr;

y is 56.2% when Z is Phe and is 65.9% when Z is Tyr; and

z is 17.9% when Z is Phe and about 28.9% when Z is Tyr.